MetaCap

Novartis (NVS) vs Vertex Pharmaceuticals (VRTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vertex Pharmaceuticals (VRTX) has outperformed Novartis (NVS) over the past year, gaining 20.7% versus a gain of 18.2%. Over five years, VRTX leads with a +180.5% price change compared with +86.5% for NVS. Novartis is the larger company by market cap ($284.18 billion vs $130.58 billion), about 2.2 times the size.

On valuation, Novartis trades at a lower forward P/E (15.1x vs 25.9x for Vertex Pharmaceuticals). Novartis pays a dividend yielding 3.10%, while Vertex Pharmaceuticals does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NVS+18.19%VRTX+20.68%
+34%+16%-2%
Nov 21, 20251 yearNov 20, 2026
NVS+84.26%VRTX+181.62%
+216%+99%-18%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NVS versus VRTX key metrics
MetricNVSVRTX
Share price$150.47$515.02
Market cap$284.18B$130.58B
1-day change-0.50%-1.08%
YTD return+9.14%+13.60%
1-year return+18.19%+20.68%
5-year return+86.46%+180.53%
P/E ratio (TTM)28.7233.14
Forward P/E15.1525.86
EPS (TTM)$5.24$15.54
Dividend yield3.10%0.00%
Annual dividend$4.67$0.00
Revenue (latest FY)—$12.00B
Revenue growth (YoY)—+8.90%
Net income (latest FY)$13.98B$3.95B
Gross margin—86.24%
Operating margin—34.77%
Net margin—32.94%
52-week high$170.46$568.67
52-week low$126.50$412.27
Distance from 52-week high-11.73%-9.43%
Analyst consensusholdbuy
Avg. price target upside+4.41%+15.60%
Average volume2.18M1.25M
Shares outstanding1.89B253.54M
Employees75,2676,400
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Novartis is about 2.2 times larger than Vertex Pharmaceuticals by market value ($284.18B vs $130.58B).
  • Novartis offers a meaningfully higher dividend yield (3.10% vs 0.00%).

About Novartis

NVS stock →

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 75,267 employees

About Vertex Pharmaceuticals

VRTX stock →

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 6,400 employees

NVS vs VRTX FAQ

Which is bigger, Novartis or Vertex Pharmaceuticals?

Novartis (NVS) is larger, with a market capitalization of $284.18B compared with $130.58B for Vertex Pharmaceuticals (VRTX).

Which stock has performed better over the past year, NVS or VRTX?

VRTX returned +20.68% over the past 12 months, compared with +18.19% for NVS (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, NVS or VRTX?

NVS has the lower trailing P/E at 28.7, versus 33.1 for VRTX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Novartis or Vertex Pharmaceuticals?

Novartis pays a dividend yielding 3.10%, while Vertex Pharmaceuticals does not currently pay a regular dividend.

Are Novartis and Vertex Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons